 |
PDBsum entry 1c9p
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
1c9p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chain A:
E.C.3.4.21.4
- trypsin.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Preferential cleavage: Arg-|-Xaa, Lys-|-Xaa.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
293:93
(1999)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
|
|
U.Rester,
W.Bode,
M.Moser,
M.A.Parry,
R.Huber,
E.Auerswald.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The serine proteinase plasmin is, together with tissue-type plasminogen
activator (tPA) and urokinase-type plasminogen activator (uPA), involved in the
dissolution of blood clots in a fibrin-dependent manner. Moreover, plasmin plays
a key role in a variety of other activation cascades such as the activation of
metalloproteinases, and has also been implicated in wound healing, pathogen
invasion, cancer invasion and metastasis. The leech-derived (Hirudo medicinalis)
antistasin-type inhibitor bdellastasin represents a specific inhibitor of
trypsin and plasmin and thus offers a unique opportunity to evaluate the concept
of plasmin inhibition. The complexes formed between bdellastasin and bovine as
well as porcine beta-trypsin have been crystallised in a monoclinic and a
tetragonal crystal form, containing six molecules and one molecule per
asymmetric unit, respectively. Both structures have been solved and refined to
3.3 A and 2.8 A resolution. Bdellastasin turns out to have an antistasin-like
fold exhibiting a bis-domainal structure like the tissue kallikrein inhibitor
hirustasin. The interaction between bdellastasin and trypsin is restricted to
the C-terminal subdomain of bdellastasin, particularly to its primary binding
loop, comprising residues Asp30-Glu38. The reactive site of bdellastasin differs
from other antistasin-type inhibitors of trypsin-like proteinases, exhibiting a
lysine residue instead of an arginine residue at P1. A model of the
bdellastasin-microplasmin complex has been created based on the X-ray
structures. Our modelling studies indicate that both trypsin and microplasmin
recognise bdellastasin by interactions which are characteristic for canonically
binding proteinase inhibitors. On the basis of our three-dimensional structures,
and in comparison with the tissue-kallikrein-bound and free hirustasin and the
antistasin structures, we postulate that the binding of the inhibitors toward
trypsin and plasmin is accompanied by a switch of the primary binding loop
segment P5-P3. Moreover, in the factor Xa inhibitor antistasin, the core of the
molecule would prevent an equivalent rotation of the P3 residue, making exosite
interactions of antistasin with factor Xa imperative. Furthermore, Arg32 of
antistasin would clash with Arg175 of plasmin, thus impairing a favourable
antistasin-plasmin interaction and explaining its specificity.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 3.
Figure 3. Interaction of the binding loop Asp30 (P5) to Glu38 (P4 ) of bdellastasin with porcine trypsin and micro-
plasmin. Stereo view of the interaction between the binding loop of bdellastasin (yellow) with (a) trypsin and with
(b) plasmin. The trypsin and the plasmin molecules are represented as stick models superimposed with transparent
electrostatic potential surfaces. Positively and negatively charged regions are coloured blue and red, respectively.
|
 |
Figure 5.
Figure 5. Superposition of antistasin-type inhibitors.
(a) Stereo superposition of bdellastasin (blue), tissue-kal-
likrein-bound hirustasin (green), and the N-terminal
(red) and the C-terminal (magenta) domain of antistasin.
The superposition is based on the C
a
atoms of residues
24-52 of hirustasin and residues 28-55 and 83-110 of the
N and C-terminal domains of antistasin, respectively.
The N and C-terminal subdomains are indicated.
(b) Stereo superposition of the N-terminal subdomains
of bdellastasin (blue), tissue-kallikrein-bound hirustasin
(green), and subdomains Nn (red) and Cn (magenta) of
antistasin. The N and C termini are marked and the
residues Glu15 and Glu69 of the interface contact loops
of N and C-terminal subdomains of antistasin are high-
lighted. Yellow connections indicate disulphide bridges.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(1999,
293,
93-0)
copyright 1999.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.D.Smith,
M.Carson,
A.M.Friedman,
M.M.Skinner,
L.Delucas,
L.Chantalat,
L.Weise,
T.Shirasawa,
and
D.Chattopadhyay
(2002).
Crystal structure of human L-isoaspartyl-O-methyl-transferase with S-adenosyl homocysteine at 1.6-A resolution and modeling of an isoaspartyl-containing peptide at the active site.
|
| |
Protein Sci,
11,
625-635.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
U.Rester,
M.Moser,
R.Huber,
and
W.Bode
(2000).
L-Isoaspartate 115 of porcine beta-trypsin promotes crystallization of its complex with bdellastasin.
|
| |
Acta Crystallogr D Biol Crystallogr,
56,
581-588.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
');
}
}
 |
|